Spots Global Cancer Trial Database for daunorubicin
Every month we try and update this database with for daunorubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | NCT03286634 | Down Syndrome Acute Lymphobla... Childhood Cance... | Daunorubicin Prednisolone Vincristine Epirubicin E-coli L-aspara... 6-Mercaptopurin... Methotrexate Hydrocortisone Cytarabine Cyclophosphamid... | 0 Years - 20 Years | National Hospital Organization Nagoya Medical Center | |
| Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | NCT00703820 | Acute Myeloid L... | Cytarabine Daunorubicin Etoposide Clofarabine CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008 | NCT01953770 | Childhood Acute... | PEG-L-asparagin... PEG-L-asparagin... E.coli L-aspara... High-dose Metho... Low-dose Methot... Triple intrathe... Cranial irradia... Daunorubicin | 1 Year - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | NCT03897127 | Acute Myeloid L... | Cytarabine Daunorubicin CPX-351 | 18 Years - | University of Ulm | |
| Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | NCT00715637 | Secondary Acute... | Daunorubicin an... Amonafide and C... | 18 Years - | Antisoma Research | |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | NCT04801797 | Acute Myeloid L... | Cytarabine Idarubicin Daunorubicin Liposomal dauno... Venetoclax Azacitidine | 18 Years - | Massachusetts General Hospital | |
| S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00109837 | Leukemia | filgrastim cyclophosphamid... cytarabine daunorubicin dexamethasone doxorubicin leucovorin mercaptopurine methotrexate mitoxantrone Asparaginase prednisone thioguanine vincristine radiation thera... allopurinol bactrim | 18 Years - 64 Years | SWOG Cancer Research Network | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| AflacLL1901 (CHOA-AML) | NCT04326439 | Acute Myeloid L... AML, Childhood | Cytarabine Daunorubicin Erwinase Etoposide Gemtuzumab ozog... Stem cell trans... Sorafenib | - 21 Years | Emory University | |
| Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | NCT04562792 | Relapsed Pediat... Relapsed Pediat... Refractory Acut... Refractory Acut... | Daunorubicin | 1 Year - 21 Years | Children's Mercy Hospital Kansas City | |
| A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | NCT01773408 | Myelogenous Leu... | RO5503781 MBP RO5503781 SDP Idarubicin Daunorubicin Cytarabine | 18 Years - | Hoffmann-La Roche | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | NCT02894645 | Acute Lymphobla... | Prednisolone Dexamethasone L-Asparaginase Vincristine Methotrexate Daunorubicin Doxorubicin Cyclophosphamid... Cytarabine 6-Mercaptopurin... Thioguanine Fludarabine Imatinib | 1 Year - 17 Years | National University Hospital, Singapore | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| Optimum Induction Therapy of Low-risk APL | NCT05832320 | Acute Promyeloc... Induction Thera... Oral | Etoposide Daunorubicin | 18 Years - 75 Years | Peking University People's Hospital | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | NCT04817241 | Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Cytarabine Daunorubicin Decitabine and ... Venetoclax | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | NCT03836209 | Acute Myeloid L... | Gilteritinib Midostaurin Daunorubicin Cytarabine | 18 Years - 70 Years | PrECOG, LLC. | |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | NCT00130195 | Acute Lymphobla... | imatinib cyclophosphamid... daunorubicin vincristine prednisolone methotrexate cytarabine dexamethasone | 15 Years - 64 Years | Japan Adult Leukemia Study Group | |
| A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. | NCT00002093 | Sarcoma, Kaposi HIV Infections | Daunorubicin (l... Bleomycin sulfa... Vincristine sul... Doxorubicin hyd... | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00651261 | Leukemia | cytarabine daunorubicin midostaurin placebo dexamethasone a... | 18 Years - 59 Years | Alliance for Clinical Trials in Oncology | |
| Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | NCT03568994 | Acute Myeloid L... | Atovaquone Cytarabine Daunorubicin Etoposide Gemtuzumab Ozog... | 1 Month - 20 Years | Baylor College of Medicine | |
| LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | NCT00526305 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone L-Asparaginase Mitoxantrone Cytosine Arabin... Hydrocortisone Mercaptopurine Cyclophosphamid... Dexamethasone | - 65 Years | PETHEMA Foundation | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | NCT03709758 | Acute Myeloid L... | Venetoclax Daunorubicin Cytarabine | 18 Years - 60 Years | Dana-Farber Cancer Institute | |
| LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia | NCT00526409 | Acute Lymphobla... | Prednisolone Daunorubicin Vincristine L-Asparaginase Cyclophosphamid... Methotrexate Cytosine Arabin... | - 16 Years | PETHEMA Foundation | |
| Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | NCT04440267 | Acute Leukemia ... | vincristine daunorubicin cyclophosphamid... L-Asparaginase prednisone mercaptopurine methotrexate dexamethasone Tyrosine kinase... | 14 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | NCT02036489 | Acute Lymphobka... | Vincristine Daunorubicin Prednisone L-asparaginase Ciclophosphamid... Metotrexate ARA-C Hidrocortisone Mercaptopurine VP-16 Dexametasone | 15 Years - | PETHEMA Foundation | |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | NCT02003222 | Acute Lymphobla... B Acute Lymphob... | Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging | 30 Years - 70 Years | National Cancer Institute (NCI) | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | NCT02343939 | Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine Decitabine Azacitidine | 18 Years - | Gilead Sciences | |
| Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | NCT03390387 | Childhood Acute... | Dexamethasone c... Dexamethasone i... Dexamethasone Methylprednisol... Daunorubicin Idarubicin Bortezomib Second phase of... Standard induct... Standard consol... | 1 Year - 50 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | NCT02660762 | Leukaemia,Lymph... | Vincristine Daunorubicin Pegaspargase Prednisone Intrathecal Met... Cyclophosphamid... Cytarabine 6-Mercaptopurin... Methotrexate Etoposide dexamethasone thioguanine intrathecal cyt... | 18 Years - 35 Years | Sun Yat-sen University | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | NCT02403310 | Leukemia Acute Myeloid L... AML | Selinexor Daunorubicin Cytarabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | NCT05660473 | Precursor Cell ... | Vincristine Daunorubicin Cyclophosphamid... Pegaspargase Prednisone Cytarabine 6-mercaptopurin... Dexamethasone Methotrexate Venetoclax | 14 Years - 60 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | NCT06124157 | B Acute Lymphob... | Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine | 366 Days - 46 Years | National Cancer Institute (NCI) | |
| A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | NCT02283177 | Newly Diagnosed... | crenolanib cytarabine daunorubicin idarubicin | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | NCT02828358 | Acute Leukemia ... B Acute Lymphob... Mixed Phenotype... | Azacitidine Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Hydrocortisone ... Laboratory Biom... Leucovorin Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Pharmacological... Prednisolone Thioguanine Vincristine Vincristine Sul... | - 364 Days | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | NCT02003222 | Acute Lymphobla... B Acute Lymphob... | Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging | 30 Years - 70 Years | National Cancer Institute (NCI) | |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02085408 | Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | Daunorubicin Cytarabine Clofarabine Decitabine Observation Allogeneic hema... | 60 Years - | Eastern Cooperative Oncology Group | |
| A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | NCT02326584 | Acute Myeloid L... Acute Myelogeno... | Standard dose c... SGN-CD33A Daunorubicin High dose cytar... | 18 Years - | Seagen Inc. | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | NCT02582359 | Acute Myeloid L... | MLN9708 Cytarabine Daunorubicin | 60 Years - | Massachusetts General Hospital | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | NCT03286634 | Down Syndrome Acute Lymphobla... Childhood Cance... | Daunorubicin Prednisolone Vincristine Epirubicin E-coli L-aspara... 6-Mercaptopurin... Methotrexate Hydrocortisone Cytarabine Cyclophosphamid... | 0 Years - 20 Years | National Hospital Organization Nagoya Medical Center | |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | NCT02343939 | Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine Decitabine Azacitidine | 18 Years - | Gilead Sciences | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00651261 | Leukemia | cytarabine daunorubicin midostaurin placebo dexamethasone a... | 18 Years - 59 Years | Alliance for Clinical Trials in Oncology | |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | NCT05886049 | Acute Myeloid L... Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | NCT03135028 | Hematologic Mal... Acute Myeloid L... | Entospletinib Daunorubicin Cytarabine | 18 Years - | Gilead Sciences | |
| Treatment of High Risk Adult Acute Lymphoblastic Leukemia | NCT00853008 | Acute Lymphobla... | Vincristine Daunorubicin Prednisone Mitoxantrone Cytosine Arabin... Dexamethasone Methotrexate (M... Cytarabine ASP Mercaptopurine Teniposide Hydrocortisone | 16 Years - | PETHEMA Foundation | |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | NCT04778397 | Acute Myeloid L... | Magrolimab Venetoclax Azacitidine Cytarabine Daunorubicin Idarubicin Steroidal Eye D... | 18 Years - | Gilead Sciences | |
| A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | NCT02326584 | Acute Myeloid L... Acute Myelogeno... | Standard dose c... SGN-CD33A Daunorubicin High dose cytar... | 18 Years - | Seagen Inc. | |
| Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | NCT02198482 | Acute Myeloid L... High-risk Myelo... | Volasertib Cytarabine Daunorubicin Mitoxantrone | 18 Years - | University of Ulm | |
| Protocol in Acute Myeloid Leukemia With FLT3-ITD | NCT01477606 | Acute Myeloid L... | Midostaurin Cytarabine Daunorubicin | 18 Years - 70 Years | University of Ulm | |
| AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | NCT00180128 | Leukemia, Promy... | all-trans retin... idarubicin mitoxantrone daunorubicin cytarabine | 16 Years - | Technische Universität Dresden | |
| AflacLL1901 (CHOA-AML) | NCT04326439 | Acute Myeloid L... AML, Childhood | Cytarabine Daunorubicin Erwinase Etoposide Gemtuzumab ozog... Stem cell trans... Sorafenib | - 21 Years | Emory University | |
| Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML | NCT02140242 | Leukemia, Myelo... | study part 1 - ... induction cycle... | 18 Years - 65 Years | Technische Universität Dresden | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | NCT00130195 | Acute Lymphobla... | imatinib cyclophosphamid... daunorubicin vincristine prednisolone methotrexate cytarabine dexamethasone | 15 Years - 64 Years | Japan Adult Leukemia Study Group | |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02085408 | Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | Daunorubicin Cytarabine Clofarabine Decitabine Observation Allogeneic hema... | 60 Years - | Eastern Cooperative Oncology Group | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| Protocol in Acute Myeloid Leukemia With FLT3-ITD | NCT01477606 | Acute Myeloid L... | Midostaurin Cytarabine Daunorubicin | 18 Years - 70 Years | University of Ulm | |
| Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | NCT02914977 | Acute Lymphocyt... Acute Myeloid L... | Daunorubicin | 18 Years - | University of Kansas Medical Center | |
| Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | NCT04562792 | Relapsed Pediat... Relapsed Pediat... Refractory Acut... Refractory Acut... | Daunorubicin | 1 Year - 21 Years | Children's Mercy Hospital Kansas City | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | NCT03643276 | Acute Lymphobla... | Blinatumomab Bortezomib Cyclophosphamid... Cytarabine Daunorubicin Myocet Dexamethasone Doxorubicin Etoposide Fludarabine Pho... Ifosfamide 6-Mercaptopurin... Methotrexate Pegaspargase Prednisolone Tioguanin Vincristine Vindesine Erwinase | - 17 Years | University Hospital Schleswig-Holstein |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
